請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50630
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄭永銘 | |
dc.contributor.author | Wei-Chou Lin | en |
dc.contributor.author | 林維洲 | zh_TW |
dc.date.accessioned | 2021-06-15T12:49:41Z | - |
dc.date.available | 2021-08-26 | |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-07-21 | |
dc.identifier.citation | 1. Society AC: Cancer Facts & Figures. In. Atlanta; 2015.
2. Factsheets SCS: Bladder Cancer. In. Edited by Institute NC. Bethesda; 2015. 3. Bellmunt J, Albiol S, Suarez C, Albanell J: Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Critical reviews in oncology/hematology 2009, 69(3):211-222. 4. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000, 18(17):3068-3077. 5. Sio TT, Ko J, Gudena VK, Verma N, Chaudhary UB: Chemotherapeutic and targeted biological agents for metastatic bladder cancer: a comprehensive review. International journal of urology : official journal of the Japanese Urological Association 2014, 21(7):630-637. 6. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, Ferlay J: Worldwide burden of cervical cancer in 2008. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011, 22(12):2675-2686. 7. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer 2010, 127(12):2893-2917. 8. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. Journal of clinical pathology 2002, 55(4):244-265. 9. Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pearson DL, Insalaco S: Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007, 25(19):2804-2810. 10. Yee GP, de Souza P, Khachigian LM: Current and potential treatments for cervical cancer. Current cancer drug targets 2013, 13(2):205-220. 11. Orlowski RZ, Kuhn DJ: Proteasome inhibitors in cancer therapy: lessons from the first decade. Clinical cancer research : an official journal of the American Association for Cancer Research 2008, 14(6):1649-1657. 12. Ciechanover A: The ubiquitin-proteasome pathway: on protein death and cell life. The EMBO journal 1998, 17(24):7151-7160. 13. Welchman RL, Gordon C, Mayer RJ: Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nature reviews Molecular cell biology 2005, 6(8):599-609. 14. Deshaies RJ, Joazeiro CA: RING domain E3 ubiquitin ligases. Annual review of biochemistry 2009, 78:399-434. 15. Pan ZQ, Kentsis A, Dias DC, Yamoah K, Wu K: Nedd8 on cullin: building an expressway to protein destruction. Oncogene 2004, 23(11):1985-1997. 16. Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M, Schulman BA: Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 2008, 134(6):995-1006. 17. Ohh M, Kim WY, Moslehi JJ, Chen Y, Chau V, Read MA, Kaelin WG, Jr.: An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO reports 2002, 3(2):177-182. 18. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S et al: An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009, 458(7239):732-736. 19. Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D, Pan Y, Ding C, Qian J, Wu L et al: The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer research 2012, 72(13):3360-3371. 20. Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA, Milhollen M, Blakemore S, Thomas M, Berger A et al: Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2013, 19(13):3577-3590. 21. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST et al: Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010, 115(18):3796-3800. 22. Kuo KL, Ho IL, Shi CS, Wu JT, Lin WC, Tsai YC, Chang HC, Chou CT, Hsu CH, Hsieh JT et al: MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies. Cancer letters 2015, 363(2):127-136. 23. Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E, Langston SP et al: MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010, 116(9):1515-1523. 24. Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H, Tayber O, Hather G, Liu R, Narayanan U et al: Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. Cancer research 2013, 73(1):225-234. 25. Boulikas T, Vougiouka M: Cisplatin and platinum drugs at the molecular level. (Review). Oncology reports 2003, 10(6):1663-1682. 26. Yu HJ, Tsai TC, Hsieh TS, Chiu TY: Characterization of a newly established human bladder carcinoma cell line, NTUB1. Journal of the Formosan Medical Association = Taiwan yi zhi 1992, 91(6):608-613. 27. Sharma A, Singh K, Almasan A: Histone H2AX phosphorylation: a marker for DNA damage. Methods in molecular biology (Clifton, NJ) 2012, 920:613-626. 28. Tanaka T, Halicka D, Traganos F, Darzynkiewicz Z: Cytometric analysis of DNA damage: phosphorylation of histone H2AX as a marker of DNA double-strand breaks (DSBs). Methods in molecular biology (Clifton, NJ) 2009, 523:161-168. 29. Deng X, Xiao L, Lang W, Gao F, Ruvolo P, May WS, Jr.: Novel role for JNK as a stress-activated Bcl2 kinase. The Journal of biological chemistry 2001, 276(26):23681-23688. 30. Burlacu A: Regulation of apoptosis by Bcl-2 family proteins. Journal of cellular and molecular medicine 2003, 7(3):249-257. 31. Tabas I, Ron D: Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nature cell biology 2011, 13(3):184-190. 32. Huang KH, Kuo KL, Chen SC, Weng TI, Chuang YT, Tsai YC, Pu YS, Chiang CK, Liu SH: Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells. PloS one 2012, 7(3):e33615. 33. Hitomi J, Katayama T, Eguchi Y, Kudo T, Taniguchi M, Koyama Y, Manabe T, Yamagishi S, Bando Y, Imaizumi K et al: Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death. The Journal of cell biology 2004, 165(3):347-356. 34. Dhanasekaran DN, Reddy EP: JNK signaling in apoptosis. Oncogene 2008, 27(48):6245-6251. 35. Leppa S, Bohmann D: Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 1999, 18(45):6158-6162. 36. Bossy-Wetzel E, Bakiri L, Yaniv M: Induction of apoptosis by the transcription factor c-Jun. The EMBO journal 1997, 16(7):1695-1709. 37. Hans F, Dimitrov S: Histone H3 phosphorylation and cell division. Oncogene 2001, 20(24):3021-3027. 38. Lapenna S, Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nature reviews Drug discovery 2009, 8(7):547-566. 39. Plati J, Bucur O, Khosravi-Far R: Apoptotic cell signaling in cancer progression and therapy. Integrative biology : quantitative biosciences from nano to macro 2011, 3(4):279-296. 40. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94(4):481-490. 41. Li H, Zhu H, Xu CJ, Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94(4):491-501. 42. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. The New England journal of medicine 1999, 340(15):1144-1153. 43. Peiretti M, Zapardiel I, Zanagnolo V, Landoni F, Morrow CP, Maggioni A: Management of recurrent cervical cancer: a review of the literature. Surgical oncology 2012, 21(2):e59-66. 44. Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, Soucy TA, Milhollen MA, Yang X, Burkhardt AL et al: Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Molecular cell 2010, 37(1):102-111. 45. Lin WC, Kuo KL, Shi CS, Wu JT, Hsieh JT, Chang HC, Liao SM, Chou CT, Chiang CK, Chiu WS et al: MLN4924, a Novel NEDD8-activating enzyme inhibitor, exhibits antitumor activity and enhances cisplatin-induced cytotoxicity in human cervical carcinoma: in vitro and in vivo study. American journal of cancer research 2015, 5(11):3350-3362. 46. Nawrocki ST, Griffin P, Kelly KR, Carew JS: MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert opinion on investigational drugs 2012, 21(10):1563-1573. 47. Read MA, Brownell JE, Gladysheva TB, Hottelet M, Parent LA, Coggins MB, Pierce JW, Podust VN, Luo RS, Chau V et al: Nedd8 modification of cul-1 activates SCF(beta(TrCP))-dependent ubiquitination of IkappaBalpha. Molecular and cellular biology 2000, 20(7):2326-2333. 48. Podust VN, Brownell JE, Gladysheva TB, Luo RS, Wang C, Coggins MB, Pierce JW, Lightcap ES, Chau V: A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(9):4579-4584. 49. Kyriakis JM, Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiological reviews 2001, 81(2):807-869. 50. Cusimano A, Azzolina A, Iovanna JL, Bachvarov D, McCubrey JA, D'Alessandro N, Montalto G, Cervello M: Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell cycle (Georgetown, Tex) 2010, 9(7):1399-1410. 51. Schonthal AH: Endoplasmic reticulum stress and autophagy as targets for cancer therapy. Cancer letters 2009, 275(2):163-169. 52. Wu J, Kaufman RJ: From acute ER stress to physiological roles of the Unfolded Protein Response. Cell death and differentiation 2006, 13(3):374-384. 53. Rutkowski DT, Kaufman RJ: A trip to the ER: coping with stress. Trends in cell biology 2004, 14(1):20-28. 54. Basu A, Krishnamurthy S: Cellular responses to Cisplatin-induced DNA damage. Journal of nucleic acids 2010, 2010. 55. Salon C, Brambilla E, Brambilla C, Lantuejoul S, Gazzeri S, Eymin B: Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: relationships with CAND1 and cyclin E protein levels. The Journal of pathology 2007, 213(3):303-310. 56. Wei D, Morgan MA, Sun Y: Radiosensitization of Cancer Cells by Inactivation of Cullin-RING E3 Ubiquitin Ligases. Translational oncology 2012, 5(5):305-312. 57. Fan M, Bigsby RM, Nephew KP: The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. Molecular endocrinology (Baltimore, Md) 2003, 17(3):356-365. 58. Chairatvit K, Ngamkitidechakul C: Control of cell proliferation via elevated NEDD8 conjugation in oral squamous cell carcinoma. Molecular and cellular biochemistry 2007, 306(1-2):163-169. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50630 | - |
dc.description.abstract | 泌尿上皮細胞癌 (urothelial carcinoma; UC)是泌尿系統常見的惡性腫瘤,在台灣發生率偏高。轉移性的泌尿上皮細胞癌,需接受化學治療,但終會因化學治療抗藥性而導致病患死亡。子宮頸上皮細胞癌(cervical carcinoma, CC)是女性生殖系統常見的惡性腫瘤,全世界發生率仍在女性生殖系統上維持前三名。轉移性的子宮頸上皮癌病患中,許多病人會因抗藥性而死亡,如何抑制這兩種癌症進展及抗藥性是臨床上的重要課題。
泛素-蛋白酶系統(Ubiquitin-proteasome system)負責調控細胞內蛋白質降解及活性,與基因表達、細胞增殖、週期、分化、凋亡、DNA修復皆有相關,若調控失調常會引起腫瘤的發生。Ubiquitin-protein ligase, E3 是一個關鍵的酵素,Ubiquitin ligases 的活化又會與其成分cullin 與neural precursor cell-expressed developmentally down-regulated protein 8 (NEDD8) 結合(Nedd8分子接合作用;Neddylation)有關。利用新的藥物(MLN4924)阻斷neddylation,是治療腫瘤的新機轉,並且已經被報告與治療癌症轉移及降低化學抗藥性(chemoresistance)有關,而且其相關機制之調控推測為克服腫瘤進展及抗藥性的重要標的。吾人之假設為調控neddylation inhibition可抑制尿路上皮細胞癌及子宮頸癌之生長,並嘗試於本研究中探討細胞週期調控蛋白之變化與neddylation inhibition之相關機轉與如何調節cullin及其變化之機制,並期望能進一步在 in vivo 的動物模式中驗證。 在本研究中,我們起初發現MLN4924能有效的抑制三株泌尿上皮腫瘤細胞 NTUB1, T24 和 RT4 cell lines 的生長,且與細胞凋亡及細胞週期調控蛋白變化有關。此外也發現neddylation inhibition與其他細胞壓力反應及內質網壓力也相關。由於泌尿上皮細胞癌是transitional cell origin,我們也將MLN4924運用在兩種不同型態之子宮頸癌細胞株如ME180 (鱗狀上皮細胞癌squamous cell carcinoma) 及HeLa (腺細胞癌adenocarcinoma) cell lines上,發現MLN4924亦能抑制其生長,並證實此藥物在泌尿上皮細胞癌和子宮頸癌細胞之小鼠轉殖動物模式上,具有其活體治療之效果。更進一步,合併neddylation inhibition 與其他化療藥物(如cisplatin)亦有加成之抑癌治療效果在子宮頸癌細胞上。 吾人相信,藉由研究neddylation modulation 治療泌尿上皮細胞癌及不同型態之子宮頸上皮細胞癌,能找到新的治療模式,並能解決臨床上抗藥性及腫瘤進展的問題。 | zh_TW |
dc.description.abstract | Urothelial carcinoma (UC) is a common cancer of urinary tract and the prevalence rate is relatively high especially in Taiwan. Patients with metastatic UC are usually treated with systemic chemotherapy but still some patients with advanced UC are not responsive to chemotherapy and die of the disease. Cervical carcinoma (CC) of the uterus is a common malignant tumor of female reproductive system. Incidence of CC in the world is still in the top three on the female reproductive system. Patients with metastatic CC usually die of the disease due to tumor recurrence and resistance to the chemotherapy. To overcome the tumor progression and chemoresistance of these two kinds of cancer is still the clinical important issue.
Ubiquitin-proteasome system is responsible for intracellular protein degradation and regulation of cell activity, gene expression, cell proliferation, cell cycle regulation, differentiation, apoptosis and DNA repair. Regulation dysfunction of ubiquitin-proteasome system is associated with tumor genesis. Ubiquitin-protein ligase E3 is one major enzyme of ubiquitin ligases and neural-precursor-cell-expressed developmentally down-regulated protein 8 (NEDD8) combining with cullin, the scaffold of some E3, is essential for E3 activation. Access of the new drug (MLN4924) to block the neddylation leads to new treatments for cancer and MLN4924 has been reported to inhibit cancer cell growth and to reduce chemoresistance. The regulation of the associated molecular mechanism is important to overcome tumor progression and chemoresistance for cancer therapy. Our hypothesis is manipulation of neddylation inhibition by MLN4924 can suppress the tumor growth of UC and CC. We try to explore the changes of cell cycle regulatory proteins and neddylation inhibition associated mechanism and the control of cullin to further verify in animal models. In this study, we initially found that MLN4924 can effectively inhibit the growth of transitional cell origin NTUB1, T24 and RT4 cell lines and associated with cell apoptosis and cell cycle regulation. In addition, the neddylation inhibition can induce cell stress reactions and endoplasmic reticulum (ER) stress related molecule expression. We also treated MLN4924 on the two different cell lines as ME180 (squamous cell carcinoma) and HeLa (adenocarcinoma) of the CC and found the similar change of tumor growth suppression. We also investigated MLN4924 by the xenograft animal model of mice on UC and CC cells to confirm MLN4924 treatment effect in vivo. Furthermore, to merge neddylation inhibitor and other chemotherapy drug such as cisplatin, we also demonstrated the combining and synergistic antitumor therapeutic efficacy on CC. In the future, we believe that by studying the neddylation modulation on UC and CC, we will find the new treatment model to overcome the clinical issue of chemoresistance and tumor progression of many kinds of carcinomas and improve the clinical treatment efficacy for cancer. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T12:49:41Z (GMT). No. of bitstreams: 1 ntu-105-D98444001-1.pdf: 2811768 bytes, checksum: 9ac3b6adde5f8b16dbc966b84788340b (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 口試委員會審定書……………………………………………………… I
誌謝…………………………………………………………….………. II 中文摘要………………………………………………………………. III 英文摘要……………………………………………………………… V Chapter 1 Introduction……………………………………………. 1 Chapter 2 Materials and Methods………………………………... 5 2.1 Cell culture…………………………………………………… 5 2.2 Reagents and antibodies……………………………..……….. 6 2.3 Measurement of cell viability………………..……………….. 7 2.4 Western blot……………………………..……………………. 7 2.5 Analysis of apoptosis by fluorescence-activated cell sorting…. 8 2.6 Cell proliferation assay………………………...……………… 9 2.7 Cell cycle analysis by flow cytometry…………………………. 9 2.8 In vivo xenograft experiments…………………………………. 9 2.9 Statistical analysis.………………………..……………………. 10 Chapter 3 Results………….…………………………………………. 12 3.1 MLN4924 reduced cell viability and induced caspase-dependent apoptosis in human urothelial tumor cells……………...………. 12 3.2 MLN4924 activated ER stress and stress-related signaling molecules in human urothelial tumor cells………..................... 13 3.3 MLN4924 leads G2/M cell cycle arrest in human urothelial tumor cells…………………................. 14 3.4 MLN4924 significantly inhibited the growth of xenografted UC tumors in SCID mice…………………….……………… 15 3.5 MLN4924 inhibited cell viability and induced apoptosis in human CC cells…………..…….……………………………... 16 3.6 MLN4924 activated apoptotic regulators, and influenced Bid and Bcl-2 in human CC cells…………………….………..….. 17 3.7 MLN4924 elicited cellular stress and ER stress-related signaling molecules in human CC cells……………...………………. 18 3.8 MLN4924 suppressed cell proliferation with interruption of cell cycle in human CC cells………………………………........ 18 3.9 MLN4924 significantly suppressed the xenografted CC tumor Cell growth in Nu/Nu nude mice……………………………... 19 3.10 Cisplatin-induced cytotoxicity was increased by MLN4924 in human CC cells……………………..……………………… 20 3.11 MLN4924 enhanced the Cisplatin-induced antitumor effect in xenograft Nu/Nu nude mice bearing with human CC cells…. 21 Chapter 4 Discussion……………………………………………….. 22 4.1 Insights of the study…………………………………………... 22 4.2 The present study and findings on neddylation and MLN4924. 22 4.2.1 Roles of MLN4924 on neddylation and cancer cells…..….. 22 4.2.2 Roles of MLN4924 on cell cycle regulation and apoptosis.. 23 4.2.3 Roles of MLN4924 on cell stress and ER stress………….. 24 4.2.4 Roles of MLN4924 and cisplatin for the in vivo study……. 25 4.3 The future clinical relevance of neddylation inhibition………. 26 Chapter 5 Conclusion………………………………………………. 28 References…………………………………………………………… 29 圖目錄 Figure 1 MLN4924 reduced cell viability and induced apoptosis in human urothelial tumor cells………………………………...34 Figure 2 MLN4924 induced caspase activation, PARP cleavage and downregulated phospho-Bcl2 proteins in human urothelial tumor cells………………………………………………….. 35 Figure 3 MLN4924 activated stress-related and ER stress-related apoptosis molecules in human urothelial tumor cells……….36 Figure 4 The effects of MLN4924 on cell cycle progression in human urothelial tumor cells………………………………………...37 Figure 5 The effect of MLN4924 on cell cycle regulatory proteins in human urothelial tumor cells……………………………….. 38 Figure 6 MLN4924 significantly inhibited the growth of human urothelial carcinoma xenografts in vivo……………………. 39 Figure 7 MLN4924 has significant effects on viability inhibition and apoptosis of human cervical carcinoma cells………………. 40 Figure 8 MLN4924 induced activations of caspases, PARP, phospho-Histone H2A.X, Bid, and decreased Bcl-2 phosphorylation in human cervical carcinoma cells…….......42 Figure 9 MLN4924 elicited cellular stress and ER stress-related signaling in human cervical carcinoma cells………….……. 43 Figure 10 MLN4924 reduced cell proliferation and interfered with cell cycle mediators in human cervical carcinoma cells…………44 Figure 11 MLN4924 significantly reduced the tumor growth of human cervical carcinoma xenografts in vivo……………………… 45 Figure 12 MLN4924 potentiated cisplatin-induced cytotoxicity in human cervical carcinoma cells……………………………………. 46 Figure 13 The anti-tumor efficacy of the combination of cisplatin and MLN4924 demonstrated in a xenograft model of human cervical carcinoma………………………………………….. 48 | |
dc.language.iso | en | |
dc.title | Neddylation抑制物MLN4924在泌尿上皮細胞癌及子宮頸癌藥物治療上所扮演之角色 | zh_TW |
dc.title | The Role of Neddylation Inhibitor MLN4924 on Urothelial Carcinoma and Cervical Carcinoma Treatment | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 劉興華,毛翠蓮,黃國皓,林家齊 | |
dc.subject.keyword | 泌尿上皮細胞癌,子宮頸癌,抗藥性,泛素-蛋白?系?,Nedd8分子接合作用, | zh_TW |
dc.subject.keyword | Urothelial carcinoma,Cervical Carcinoma,Chemoresistance,Ubiquitin-proteasome system,Nedd8 (neural-precursor-cell-expressed developmentally down-regulated protein 8),Neddylation, | en |
dc.relation.page | 49 | |
dc.identifier.doi | 10.6342/NTU201601177 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-07-21 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 病理學研究所 | zh_TW |
顯示於系所單位: | 病理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 2.75 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。